Presentation is loading. Please wait.

Presentation is loading. Please wait.

(A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet.

Published byLiana Tanuwidjaja Modified over 5 years ago

Similar presentations

Presentation on theme: "(A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet."— Presentation transcript:

1 (A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (B) Secondary cardiovascular outcome: risk of all-cause mortality between TAPT versus DAPT. (C) Secondary cardiovascular outcome: risk of myocardial infarction between TAPT versus DAPT. (D) Secondary cardiovascular outcome: risk of target lesion revascularisation (TLR) between TAPT versus DAPT. (E) Secondary cardiovascular outcome: risk of target vessel revascularisation (TVR) between TAPT versus DAPT. (F) Secondary cardiovascular outcome: risk of stent thrombosis between TAPT versus DAPT. Sripal Bangalore et al. Open Heart 2014;1:e000068 ©2014 by British Cardiovascular Society

Download ppt "(A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet."

Similar presentations

Trial profile Fox K et al. Lancet 2008;372:807-16.

Trial profile Fox K et al. Lancet 2008;372:
Two-Year Clinical Outcomes Yan Li MD., PhD. On behalf of FIREMAN Investigators Associated Professor of Department of Cardiology of Xijing Hospital Fourth.

Two-Year Clinical Outcomes Yan Li MD., PhD. On behalf of FIREMAN Investigators Associated Professor of Department of Cardiology of Xijing Hospital Fourth.
EXAMINATION Objective Assess the safety and performance of a new-generation DES vs. a BMS in the setting of primary PCI for treatment of patients with.

EXAMINATION Objective Assess the safety and performance of a new-generation DES vs. a BMS in the setting of primary PCI for treatment of patients with.
RESOLUTE US One-Year Clinical Outcomes from the Pivotal Multicenter RESOLUTE US Study Objective To evaluate the clinical effectiveness of the Resolute.

RESOLUTE US One-Year Clinical Outcomes from the Pivotal Multicenter RESOLUTE US Study Objective To evaluate the clinical effectiveness of the Resolute.
¨ 8 European countries, 48 centres Stent implantation Double-blind randomisation n = 1005 Clopidogrel 300mg od Aspirin 325mg od Clopidogrel 75mg od Aspirin.

¨ 8 European countries, 48 centres Stent implantation Double-blind randomisation n = 1005 Clopidogrel 300mg od Aspirin 325mg od Clopidogrel 75mg od Aspirin.
TLR Funnel plot (according to outcomes) for studies included in the meta-analysis Death A TVR B MACE DC 0.01 0.1 1 10 100 0.0 0.4 0.8 1.2 1.6 SE(log OR)

TLR Funnel plot (according to outcomes) for studies included in the meta-analysis Death A TVR B MACE DC SE(log OR)
Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.

Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.
Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Efficacy and Safety of Dual Antiplatelet Therapy.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Efficacy and Safety of Dual Antiplatelet Therapy.
on behalf of the ABSORB II Investigators

on behalf of the ABSORB II Investigators
Current Problems in Cardiology

Current Problems in Cardiology
The Evolution of Myocardial Infarction: When the Truths We Hold To Be Self-Evident No Longer Have Evidence  David D. Waters, MD, Sripal Bangalore, MD,

The Evolution of Myocardial Infarction: When the Truths We Hold To Be Self-Evident No Longer Have Evidence  David D. Waters, MD, Sripal Bangalore, MD,
Circ Cardiovasc Interv

Circ Cardiovasc Interv
Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention  Chirag Bavishi, MD, MPH,

Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention  Chirag Bavishi, MD, MPH,
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Robert W. Yeh et al. JACC 2017;70:

Robert W. Yeh et al. JACC 2017;70:
Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial
Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials
Impact of risk factors and age of initiation of therapy on the distribution of lifespan gain. ‘National average risk’ refers to a cohort beginning at age.

Impact of risk factors and age of initiation of therapy on the distribution of lifespan gain. ‘National average risk’ refers to a cohort beginning at age.

Similar presentations

Ads by Google